Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

December 16, 2019December 18, 2019

CHMP Recommends EU Approval of Darzalex Combo as First-line Treatment for Transplant-eligible Myeloma Patients

News

The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Darzalex (daratumumab), in combination with standard pre-transplant therapy, for the treatment of newly diagnosed multiple myeloma patients who are ... Read more

December 4, 2019December 12, 2019

Venclexta-Darzalex Combos Show Strong Response Rates in Multiple Myeloma Trial, Early Data Show

News

Adding the antibody Darzalex (daratumumab) to Venclexta (venetoclax), a lymphoma and leukemia treatment, is a promising approach for multiple myeloma patients who failed prior treatment, particularly those with a common ... Read more

December 3, 2019December 4, 2019

Venclexta Safe and Effective for Certain Multiple Myeloma Patients, Trial Data Show

News

Venclexta (venetoclax), approved to treat lymphoma and leukemia, may also be promising for multiple myeloma patients who failed at least one prior treatment, particularly those with a common genetic abnormality ... Read more

November 8, 2019

Bispecific Antibody in Phase 1 Multiple Myeloma Trial Named Orphan Drug by FDA, Teneobio Announces

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Teneobio‘s bispecific antibody TNB-383B as a possible treatment of multiple myeloma. Orphan drug designation provides Teneobio with benefits, including ... Read more

October 11, 2019October 11, 2019

Pomalyst Combo Appears Effective in Multiple Myeloma Patients Refractory to Revlimid, Trial Reports

News

Multiple myeloma patients who failed to respond to treatment with oral Revlimid (lenalidomide) may benefit from by being treated soon afterward with oral Pomalyst (pomalidomide) and low-dose dexamethasone, results of a ... Read more

September 11, 2019

Cancer Patients Around the World to Receive Henry Schein ‘Comfort Kits’

News

Henry Schein, a foundation devoted to promoting dental and medical health, has produced more than 27,000 comfort kits for people fighting cancer in the U.S. The kits, which are meant to ... Read more

August 28, 2019

GSK’s Belantamab Mafodotin Shows Promise for Relapsed or Refractory Multiple Myeloma

News

GlaxoSmithKline’s investigational antibody-drug conjugate, belantamab mafodotin (GSK2857916), demonstrated a clinically meaningful overall response rate in hard-to-treat multiple myeloma patients in a Phase 2 trial, with the trial meeting its ... Read more

August 26, 2019

Darzalex OK’d to Treat Multiple Myeloma Patients in Japan Not Eligible for Stem Cell Transplant

News

People in Japan newly diagnosed with multiple myeloma and ineligible for a stem cell transplant can now use a combination of Darzalex (daratumumab) and standard treatment, the companies behind the therapy announced. ... Read more

August 7, 2019September 10, 2019

clonoSEQ Assay Approved in New York to Measure MRD in Myeloma, Other Blood Cancers

News

The clonoSEQ Assay — a test that detects cancer cells present in very small numbers in a patient’s bone marrow, blood, or tissue sample — now is available to New ... Read more

August 5, 2019

First Patient Dosed in Phase 1 Trial of Antibody for Advanced Multiple Myeloma, Teneobio Announces

News

A Phase 1 trial evaluating Teneobio’s bispecific antibody TNB-383B as a treatment for multiple myeloma has started dosing patients. This safety and tolerability trial is recruiting people with advanced ... Read more

Pin It on Pinterest